

09/700402

1102865-0034 PCT

WO 99/59628

PCT/US99/10750

What we claim is:

1. A combination of anti-gastrin-dependent tumor therapeutic ingredients comprising:
 - 5 (i) an immunogen directed against gastrin dependent tumor growth; and
 - (ii) one or more chemotherapeutic agents.
2. The combination of claim 1, wherein the immunogen comprises a therapeutically effective amount of an anti-gastrin G17 peptide-containing immunogen.
3. The combination according to claim 2, wherein the anti-gastrin G17 immunogen is
- 10 conjugated to a Diphtheria toxoid.
4. The combination according to claim 2, wherein the anti-gastrin G17 immunogen further comprises a spacer peptide.
5. The combination according to claim 2, wherein the anti-gastrin G17 immunogen
- 15 comprises a peptide consisting of amino acid sequence pGlu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu (SEQ ID NO. 1: in the Sequence Listing).
6. The combination according to claim 2, wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, leucovorin, levamisole, cisplatin, tumor necrosis factor, and proglumide.
7. The combination of anyone of the claims 1 through 6, further comprising a
- 20 pharmaceutically acceptable carrier.
8. Use of the combination claimed according to any one of the claims 1 through 7 for the treatment of a gastrin tumor in a patient.
9. Use for the manufacture of the combination claimed in any one of the claims 1 through 7.

Add A'

AMENDED SHEET